Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Haxel

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Laryngo- Rhino- Otologie|October 15, 2019
Boris Haxel
Laryngo- Rhino- Otologie|December 12, 2018
Boris Haxel
Laryngo- Rhino- Otologie|April 25, 2022
[Management of the partial avulsions of the auricle]Jamal Huseynov, Boris Haxel, Miloš Fischer, et al.
Laryngo- Rhino- Otologie|May 9, 2020
Andreas Dietz, Boris Haxel, Andreas Müller, et al.
The Laryngoscope|August 10, 2013
Olfactory training is helpful in postinfectious olfactory loss: a randomized, controlled, multicenter studyMichael Damm, Louisa K Pikart, Heike Reimann, et al.
Oncology Research and Treatment|December 16, 2021
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID TrialUte Goerling, Thomas Gauler, Andreas Dietz, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Laryngo- Rhino- Otologie|October 15, 2019
Boris Haxel
Laryngo- Rhino- Otologie|December 12, 2018
Boris Haxel
Laryngo- Rhino- Otologie|April 25, 2022
[Management of the partial avulsions of the auricle]Jamal Huseynov, Boris Haxel, Miloš Fischer, et al.
Laryngo- Rhino- Otologie|May 9, 2020
Andreas Dietz, Boris Haxel, Andreas Müller, et al.
The Laryngoscope|August 10, 2013
Olfactory training is helpful in postinfectious olfactory loss: a randomized, controlled, multicenter studyMichael Damm, Louisa K Pikart, Heike Reimann, et al.
Oncology Research and Treatment|December 16, 2021
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID TrialUte Goerling, Thomas Gauler, Andreas Dietz, et al.
Pageof 1